6 ms·
Thanks for sharing your experience. >"... Of course the thing to emphasise is that, whilst it might break through, the vaccine still stops serious illness to a
by belter 5y ago
Thanks for sharing your experience.
>"... Of course the thing to emphasise is that, whilst it might break through, the vaccine still stops serious illness to a high degree...."
Important to note, vaccines do not protect you, its the
immune response they trigger and the level of antibodies that will protect you.
What really should be happening should be a mass vaccination program and a mass antibodies level testing program at the same time. Except for a few clinical studies, whose results are only now starting to come out I do not think any country is doing that. Frankly it puzzles me a little bit.
There is not enough data yet to see how these antibodies levels reduce with time, but there is already plenty of information to show they drop dramatically after 6 months, hence the talk now of the third shot.
Hence I think its better to say vaccines will produce level of antibodies that will protect...for now.
"Understanding mRNA COVID-19 Vaccines"
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different...
- criticaltinker 5y ago> What really should be happening should be a mass vaccination program Compulsory mass vaccination using the current vaccines poses a serious public health risk [1][2][3]. See my other comments here for more explanation and citations. For these reasons, vaccination strategies should be highly targeted towards vulnerable populations, and should be heavily supplemented by additional therapeutic modalities. > and a mass antibodies level testing program at the same time Antibody levels are used as proxy for protection [4], but higher levels of antibodies do not necessarily always translate to higher levels of protection. In fact, individuals with undetectable levels of antibodies can still have robust and durable immunity [5][6][7]. There is plenty of literature on antibody levels reducing with time [8][9], but again, antibody levels are only one aspect of a complex immune response. [1] Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein https://pubmed.ncbi.nlm.nih.gov/33909660/ https://pubmed.ncbi.nlm.nih.gov/33909660/ [2] Can we predict the limits of SARS-CoV-2 variants and their phenotypic consequences? https://www.gov.uk/government/publications/long-term-evolution-of-sars-cov-2-26-july-2021 https://www.gov.uk/government/publications/long-term-evoluti... [3] Why does drug resistance readily evolve but vaccine resistance does not? https://royalsocietypublishing.org/doi/pdf/10.1098/rspb.2016.2562 https://royalsocietypublishing.org/doi/pdf/10.1098/rspb.2016... [4] SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy https://pubmed.ncbi.nlm.nih.gov/33937733/ https://pubmed.ncbi.nlm.nih.gov/33937733/ [5] SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans https://www.nature.com/articles/s41586-021-03647-4.pdf https://www.nature.com/articles/s41586-021-03647-4.pdf [6] Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00203-2 https://www.cell.com/cell-reports-medicine/fulltext/S2666-37... [7] Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination https://www.cell.com/immunity/fulltext/S1074-7613(21)00308-3 https://www.cell.com/immunity/fulltext/S1074-7613(21)00308-3 [8] Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920668/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920668/ [9] Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection https://www.nature.com/articles/s41586-021-03696-9 https://www.nature.com/articles/s41586-021-03696-9
- civilized 5y ago> Compulsory mass vaccination using the current vaccines poses a serious public health risk [1][2][3] None of your references say this or anything remotely implying this. Backing up a provocative claim with a snowblind of irrelevant references is a shameful misinformation tactic and you should stop doing it immediately. Doing it in a public health context is particularly dangerous and frankly disgusting.
- aplummer 5y agoThanks for adding this. Compulsory mass vaccination is one of the greatest medical miracles in human history, possibly the actual single greatest. Source: https://en.wikipedia.org/wiki/Iron_lung#/media/File:Poumon_artificiel.jpg https://en.wikipedia.org/wiki/Iron_lung#/media/File:Poumon_a...
- newacct583 5y agoSecond greatest. Antibiotics take the crown.
- aplummer 5y agoI think you got me there, but it's at least up there as a big winner.
- deleted 5y ago[deleted]
- breck 5y agoAccording to a 2012 NEJM survey, #1 is anesthesia. https://www.degruyter.com/document/doi/10.1016/j.sjpain.2013.07.027/html https://www.degruyter.com/document/doi/10.1016/j.sjpain.2013... IIRC it then went X-Rays and Antibiotics, but can't find source ATM.
- criticaltinker 5y agoMy emphasis is on compulsory, but perhaps I should've been more clear. Obviously I've triggered some people here. Vaccines are powerful tools that help save lives and we should use them. But if they are used indiscriminately they can actually further endanger public health. You might be familiar with antibiotic resistance - vaccines are subject to the same potential for unexpected consequences. All of the sources I cited support this fact - it is not misinformation. Did you read any of them? Here are some excerpts for you: Excerpts from [1]: > "The spike protein receptor-binding domain (RBD) of SARS-CoV-2 is the molecular target for many vaccines and antibody-based prophylactics aimed at bringing COVID-19 under control." > "Such a narrow molecular focus raises the specter of viral immune evasion as a potential failure mode for these biomedical interventions. With the emergence of new strains of SARS-CoV-2 with altered transmissibility and immune evasion potential, a critical question is this: how easily can the virus escape neutralizing antibodies (nAbs) targeting the spike RBD?" > "Our modeling suggests that SARS-CoV-2 mutants with one or two mildly deleterious mutations are expected to exist in high numbers due to neutral genetic variation, and consequently resistance to vaccines or other prophylactics that rely on one or two antibodies for protection can develop quickly -and repeatedly- under positive selection." > "The speed at which nAb resistance develops in the population increases substantially as the number of infected individuals increases, suggesting that complementary strategies to prevent SARS-CoV-2 transmission that exert specific pressure on other proteins (e.g., antiviral prophylactics) or that do not exert a specific selective pressure on the virus (e.g., high-efficiency air filtration, masking, ultraviolet air purification) are key to reducing the risk of immune escape" > "Strategies for viral elimination should therefore be diversified across molecular targets and therapeutic modalities" Excerpts from [2]: > As vaccines against SARS-CoV-2 are deployed across populations, it is possible to create a selection pressure for variants that can escape the vaccine-acquired immune response. Over the past few months, several variants have emerged which show a reduced susceptibility to vaccine-acquired immunity, though none appears to escape entirely. These variants largely emerged before vaccination was widespread, thus selection pressure from vaccines is unlikely to have made a significant contribution to their emergence. However, as vaccines become more widespread, the transmission advantage gained by a virus that can evade vaccine-acquired immunity will increase. > There is no historic precedent for the mass administration of antiviral medication in the community as prophylaxis, apart from the use of anti influenza Neuraminidase Inhibitors, which were used to a limited extent in this way in the early phases of Influenza Pandemic of 2009 in the UK. The safety and efficacy profile must be extremely well established for a mass administration strategy to work and poor compliance will likely rapidly lead to the selection of drug resistant variants, rendering such a strategy short lived. I could go on, but that fact is your comment is not a charitable or informed response to the statements I made. [1] Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein (April 2021) https://pubmed.ncbi.nlm.nih.gov/33909660/ https://pubmed.ncbi.nlm.nih.gov/33909660/ [2] Can we predict the limits of SARS-CoV-2 variants and their phenotypic consequences? https://www.gov.uk/government/publications/long-term-evolution-of-sars-cov-2-26-july-2021 https://www.gov.uk/government/publications/long-term-evoluti...
- red_trumpet 5y agoIt's not just antibodies though. Vaccines also trigger you to get memory cells, which have a longer life span. So even if your antibody levels go down after ~6 months, and you might get infected again, your immune system will have a faster and more precise reaction, preventing a more severe course of covid.
- fy20 5y agoThis is what a lot of people do not understand. Antibodies are basically the front line soldiers fighting the virus, but there's no point keeping them deployed even after the war is over. Memory cells circulate in the blood stream for much longer - sometimes decades for other pathogens - and if they identify their target antigen, will quickly trigger an immune response and produce new antibodies. Having a high number of antibodies correlates with a strong immune response and lower rates of incidence, but that doesn't mean having a high number of antibodies is needed for that. It's really too early to say exactly how long term immune response works with this virus, as the only studies that have been completed so far are small samples sets or short time frames.
- fitzroy 5y agoI'm curious to know how much the reaction to the second or subsequent jabs correlates to antibody/immunity level. I had no reaction to the first jab and a 12-hour flu-like reaction to the second jab the next day (both Moderna). NOT having a similar reaction to a third booster would be concerning, but I wonder how much the reaction actually correlates with protection for shots beyond the first.
- belter 5y agoGood question. I think the consensus is that the two things are not related. That is the reason I argued for vaccination and testing for immunity as a single combined action for each individual. "No, vaccine side effects don’t tell you how well your immune system will protect you from COVID-19" https://theconversation.com/no-vaccine-side-effects-dont-tell-you-how-well-your-immune-system-will-protect-you-from-covid-19-158728 https://theconversation.com/no-vaccine-side-effects-dont-tel...
- mdtancsa 5y agofor what its worth, I had AZ as my first shot and it was pretty rough for 36 hours and then I was fine. My second shot of pfizer 8 weeks later barely left a sore spot on my arm. Not sure what if anything it means, but curious what will happen if I get a 3rd.
- Sunspark 5y agoI had 2 shots of AZ but the same experience. Rough initial period, but the second one was fine. I don't plan to get a third one until they make an updated vaccine for the newer variants like delta. What's the point if it's the old vaccine?
- kmonsen 5y agoData from Israel shows that a third pfeizer dose is highly effective against delta.